



## IDENTIFICAZIONE DEL *VOLUME DI TRATTAMENTO* RADIANTE NEI PAZIENTI CON *GLIOMA AD ALTO GRADO* UTILIZZANDO *L'IMAGING FUNZIONALE*

P. Navarria, E. Clerici, A.M. Ascolese, S. Tomatis, P. Mancosu, F. Alongi, E. Villa,  
T. Comito, A. Tozzi and M. Scorsetti

*Unità Operativa di Radioterapia e Radiochirurgia  
Humanitas Cancer Center Rozzano - Milano*



## Identificazione del Volume di RT in HGG utilizzando l'Imaging Funzionale

---

### RATIONALE

STANDARD OF CARE: Surgical resection, adjuvant RT and CT

Several studies to define the **Optimal Radiation Dose** and **Fractionation Schedule**

**New techniques** allow delivery of high -dose to the tumor with maximum sparing of normal brain and critical structures

The extent of tumor must be **correctly defined**

## Identificazione del Volume di RT in HGG utilizzando l'Imaging Funzionale

---

### DEFINITION OF TARGET VOLUME

CTV: **Residual tumor and resection cavity** plus 2 cm

PTV: CTV plus 3 mm

Minniti G J Neurooncol 2008; EORTC trials: Stupp R N Engl J Med 2005; Brandes AA, Eur J Cancer 2010

---

CTV1: **peritumoral edema** post-op plus 2 cm → 46 Gy

CTV2: residual tumor plus 2 cm → 60 Gy

RTOG 0525 and 8525 trials

---

CTV: **enhanced area** plus 2 cm

PTV: CTV + 5 mm

Eric L. IJROBP 2007 (MDACC)

---

GTV: **enhanced T1 and FLAIR/T2** (*pre and post MRI*)

CTV: GTV plus 2-3 cm

NCCN Guidelines 2013

---

Carbon-11-labeled methionine PET ([<sup>11</sup>C]MET-PET) uptake by normal brain parenchyma is relatively low

More precisely outline of the true extent of viable tumor tissue than MRI

# Identificazione del Volume di RT in HGG utilizzando l'Imaging Funzionale

---

## AIM , PATIENTS and METHODS

### PURPOSE

Influence of FLAIR/MRI and 11C-MET-PET in **Target Volume Definition** and **LC**

### PATIENTS and METHODS

November 2011- December 2012 102 pts newly diagnoses of HGG Surgery, concomitant RT-CT and adjuvant CT

#### 20 consecutive patients

- Simulation contrast CT scan
- Simulation T1 contrast MRI and FLAIR/T2 MRI
- Simulation [11C]MET-PET
- Preoperative T1/FLAIR/MRI

COREGISTERED



## Identificazione del Volume di RT in HGG utilizzando l'Imaging Funzionale

---

### PATIENTS

7 F 13 M median age 57 years (range 27-69 years)

Glioblastoma 13 pts

Anaplastic Astocytoma 6 pts

Anaplastic Oligodendroglioma 1 pts

RPA I:3 pts RPA II:4 pts RPA III:3 pts RPA V:10 pts

Complete Resection CR 12 pts

Subtotal Resection SR 7 pts median EOR 90.7% (60.8-99.1%)

Partial Resection PR 1 pts EOR 12%

## Identificazione del Volume di RT in HGG utilizzando l'Imaging Funzionale

---


### METHODS

CTV1: FLAIR/MRI + resection cavity + MET-PET uptake  
PTV1: CTV1 + margin 1 cm


All patients were treated on PTVI 60 Gy/30 fractions with concomitant Temozolomide

CTV2: resection cavity + postop enhanced MRI  
PTV2: CTV2 + margin 2 cm

# Identificazione del Volume di RT in HGG utilizzando l'Imaging Funzionale



# Identificazione del Volume di RT in HGG utilizzando l'Imaging Funzionale



# Identificazione del Volume di RT in HGG utilizzando l'Imaging Funzionale

## RESULTS

Pts	CTV1cc	CTV2 cc	PTV 1 cc	PTV 2 cc	MET-PET Uptake		
					Site	up to mm	SUV max
All	m 80 r 32-209	m 55 r 16-109	m 230 r 134-533	m 407 r 143-594			
12CR					4 RC 8 OS 12 IS Flair	31	nuanced ≤ 4
7 SR					3 RT 4 RT + spot 7 IS Flair	32	≥ 4
1 PR					1 RT 1 IS Flair		≥ 4

RC Resection Cavity  
 OS outside  
 IS inside  
 RT residual tumor

## Identificazione del Volume di RT in HGG utilizzando l'Imaging Funzionale

---

### RESULTS

<b>Local Relapse</b>	7/20 patients at median time 9 months (range 5-12 months) 7/20 in field progression <ul style="list-style-type: none"><li>* 4/12 CR uptake MET-PET outside of SC</li><li>* 3/7 SR 2/3 uptake residual and outside SC 1/3 uptake residual tumor</li></ul>
<b>Median OS</b>	14 months (range 6-19 months) 16 alive 4 dead (1 other cause) <ul style="list-style-type: none"><li>* 2/3: 8 and 17 months SR</li><li>* 1/3: CR with uptake up to 31 mm</li></ul>
<b>Toxicity</b>	Negligible

## Identificazione del Volume di RT in HGG utilizzando l'Imaging Funzionale

---

### CONCLUSION

The Target Volume define on contrast MRI has limitation for the **high risk of tumor target omission**

**FLAIR-MRI PTV volumes** are lower/comparable with contrast-MRI PTV  
Better **selectively** on tumor volume with major sparing of normal brain

Uptake MET-PET allowed us to define **microscopically residual tumor** not evident on postoperative MRI above all in patients underwent to complete resection

Uptake MET-PET was inside of preoperative **FLAIR-MRI images**